Home > Research > Publications & Outputs > A tale of two countries

Research

Links

Text available via DOI:

Keywords

View graph of relations

A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. / Sabin, C; CANOC UK-CHIC Collaboration.
In: HIV Medicine, Vol. 18, No. 9, 31.10.2017, p. 655-666.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Sabin, C & CANOC UK-CHIC Collaboration 2017, 'A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada', HIV Medicine, vol. 18, no. 9, pp. 655-666. https://doi.org/10.1111/hiv.12505

APA

Sabin, C., & CANOC UK-CHIC Collaboration (2017). A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. HIV Medicine, 18(9), 655-666. https://doi.org/10.1111/hiv.12505

Vancouver

Sabin C, CANOC UK-CHIC Collaboration. A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. HIV Medicine. 2017 Oct 31;18(9):655-666. Epub 2017 Apr 24. doi: 10.1111/hiv.12505

Author

Sabin, C ; CANOC UK-CHIC Collaboration. / A tale of two countries : all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. In: HIV Medicine. 2017 ; Vol. 18, No. 9. pp. 655-666.

Bibtex

@article{55ad687583684fd197c1a2fd1fa140ed,
title = "A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada",
abstract = "Objectives We sought to compare all-cause mortality of people living with HIV and accessing care in Canada and the UK. Methods Individuals from the Canadian Observational Cohort (CANOC) collaboration and UK Collaborative HIV Cohort (UK CHIC) study who were aged ≥ 18 years, had initiated antiretroviral therapy (ART) for the first time between 2000 and 2012 and who had acquired HIV through sexual transmission were included in the analysis. Cox regression was used to investigate the difference in mortality risk between the two cohort collaborations, accounting for loss to follow-up as a competing risk. Results A total of 19 960 participants were included in the analysis (CANOC, 4137; UK CHIC, 15 823). CANOC participants were more likely to be older [median age 39 years (interquartile range (IQR): 33, 46 years) vs. 36 years (IQR: 31, 43 years) for UK CHIC participants], to be male (86 vs. 73%, respectively), and to report men who have sex with men (MSM) sexual transmission risk (72 vs. 56%, respectively) (all P < 0.001). Overall, 762 deaths occurred during 98 798 person-years (PY) of follow-up, giving a crude mortality rate of 7.7 per 1000 PY [95% confidence interval (CI): 7.1, 8.3 per 1000 PY]. The crude mortality rates were 8.6 (95% CI: 7.4, 10.0) and 7.5 (95% CI: 6.9, 8.1) per 1000 PY among CANOC and UK CHIC study participants, respectively. No statistically significant difference in mortality risk was observed between the cohort collaborations in Cox regression accounting for loss to follow-up as a competing risk (adjusted hazard ratio 0.86; 95% CI: 0.72–1.03). Conclusions Despite differences in national HIV care provision and treatment guidelines, mortality risk did not differ between CANOC and UK CHIC study participants who acquired HIV through sexual transmission.",
keywords = "AIDS, antiretroviral therapy, Canada, HIV, mortality, UK",
author = "S. Patterson and S. Jose and H. Samji and A. Cescon and E. Ding and J. Zhu and J. Anderson and A.N. Burchell and C. Cooper and T. Hill and M. Hull and M.B. Klein and M. Loutfy and F. Martin and N. Machouf and J.S.G. Montaner and M. Nelson and J. Raboud and S.B. Rourke and C. Tsoukas and R.S. Hogg and C Sabin and {CANOC UK-CHIC Collaboration}",
year = "2017",
month = oct,
day = "31",
doi = "10.1111/hiv.12505",
language = "English",
volume = "18",
pages = "655--666",
journal = "HIV Medicine",
number = "9",

}

RIS

TY - JOUR

T1 - A tale of two countries

T2 - all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada

AU - Patterson, S.

AU - Jose, S.

AU - Samji, H.

AU - Cescon, A.

AU - Ding, E.

AU - Zhu, J.

AU - Anderson, J.

AU - Burchell, A.N.

AU - Cooper, C.

AU - Hill, T.

AU - Hull, M.

AU - Klein, M.B.

AU - Loutfy, M.

AU - Martin, F.

AU - Machouf, N.

AU - Montaner, J.S.G.

AU - Nelson, M.

AU - Raboud, J.

AU - Rourke, S.B.

AU - Tsoukas, C.

AU - Hogg, R.S.

AU - Sabin, C

AU - CANOC UK-CHIC Collaboration

PY - 2017/10/31

Y1 - 2017/10/31

N2 - Objectives We sought to compare all-cause mortality of people living with HIV and accessing care in Canada and the UK. Methods Individuals from the Canadian Observational Cohort (CANOC) collaboration and UK Collaborative HIV Cohort (UK CHIC) study who were aged ≥ 18 years, had initiated antiretroviral therapy (ART) for the first time between 2000 and 2012 and who had acquired HIV through sexual transmission were included in the analysis. Cox regression was used to investigate the difference in mortality risk between the two cohort collaborations, accounting for loss to follow-up as a competing risk. Results A total of 19 960 participants were included in the analysis (CANOC, 4137; UK CHIC, 15 823). CANOC participants were more likely to be older [median age 39 years (interquartile range (IQR): 33, 46 years) vs. 36 years (IQR: 31, 43 years) for UK CHIC participants], to be male (86 vs. 73%, respectively), and to report men who have sex with men (MSM) sexual transmission risk (72 vs. 56%, respectively) (all P < 0.001). Overall, 762 deaths occurred during 98 798 person-years (PY) of follow-up, giving a crude mortality rate of 7.7 per 1000 PY [95% confidence interval (CI): 7.1, 8.3 per 1000 PY]. The crude mortality rates were 8.6 (95% CI: 7.4, 10.0) and 7.5 (95% CI: 6.9, 8.1) per 1000 PY among CANOC and UK CHIC study participants, respectively. No statistically significant difference in mortality risk was observed between the cohort collaborations in Cox regression accounting for loss to follow-up as a competing risk (adjusted hazard ratio 0.86; 95% CI: 0.72–1.03). Conclusions Despite differences in national HIV care provision and treatment guidelines, mortality risk did not differ between CANOC and UK CHIC study participants who acquired HIV through sexual transmission.

AB - Objectives We sought to compare all-cause mortality of people living with HIV and accessing care in Canada and the UK. Methods Individuals from the Canadian Observational Cohort (CANOC) collaboration and UK Collaborative HIV Cohort (UK CHIC) study who were aged ≥ 18 years, had initiated antiretroviral therapy (ART) for the first time between 2000 and 2012 and who had acquired HIV through sexual transmission were included in the analysis. Cox regression was used to investigate the difference in mortality risk between the two cohort collaborations, accounting for loss to follow-up as a competing risk. Results A total of 19 960 participants were included in the analysis (CANOC, 4137; UK CHIC, 15 823). CANOC participants were more likely to be older [median age 39 years (interquartile range (IQR): 33, 46 years) vs. 36 years (IQR: 31, 43 years) for UK CHIC participants], to be male (86 vs. 73%, respectively), and to report men who have sex with men (MSM) sexual transmission risk (72 vs. 56%, respectively) (all P < 0.001). Overall, 762 deaths occurred during 98 798 person-years (PY) of follow-up, giving a crude mortality rate of 7.7 per 1000 PY [95% confidence interval (CI): 7.1, 8.3 per 1000 PY]. The crude mortality rates were 8.6 (95% CI: 7.4, 10.0) and 7.5 (95% CI: 6.9, 8.1) per 1000 PY among CANOC and UK CHIC study participants, respectively. No statistically significant difference in mortality risk was observed between the cohort collaborations in Cox regression accounting for loss to follow-up as a competing risk (adjusted hazard ratio 0.86; 95% CI: 0.72–1.03). Conclusions Despite differences in national HIV care provision and treatment guidelines, mortality risk did not differ between CANOC and UK CHIC study participants who acquired HIV through sexual transmission.

KW - AIDS

KW - antiretroviral therapy

KW - Canada

KW - HIV

KW - mortality

KW - UK

U2 - 10.1111/hiv.12505

DO - 10.1111/hiv.12505

M3 - Journal article

VL - 18

SP - 655

EP - 666

JO - HIV Medicine

JF - HIV Medicine

IS - 9

ER -